Progressive neutrophil-mediated lung damage causes much of the morbidity and mortality in cystic ®brosis (CF). Neutrophil chemoattractants implicated in CF include interleukin (IL-)8, tumour necrosis factor (TNFa) and leukotriene (LT)B 4 , but growth-related protein a (GROa), a highly potent neutrophil chemokine, has not been investigated. Atopic status has been considered to contribute to the marked heterogeneity of pulmonary disease in CF. We hypothesized that GROa may be produced in biologically-signi®cant amounts in the CF lung, and that enhanced production of GROa, IL-8 or LTB 4 may contribute to the poorer lung function seen in atopic CF patients compared to non-atopic CF patients. GROa, IL-8 and LTB 4 levels in the sputum of atopic and non-atopic CF patients were assessed by immunoassays, and GROa and IL-8 levels were also assessed in the plasma of CF patients and normal controls. As expected, there were high levels of IL-8 and LTB 4 in most CF sputum samples, and IL-8 levels were higher in CF plasma than in control plasma (P0Á02). In contrast, GROa was undetectable (55 pg ml
Introduction
Unrestrained local in¯ammation contributes signi®cantly to progressive lung damage in cystic ®brosis (CF), mediated primarily by toxic products of neutrophils, especially oxygen free radicals and elastase. The mobilization of neutrophils from the circulation into the lungs is a complex series of events largely aected by adhesion molecule interactions and the production of chemoattractant lipids and cytokines, including leukotriene (LT)B 4 , tumour necrosis factor (TNFa), interleukin (IL)-1, neutrophilactivating peptide (ENA-78) and IL-8. LTB 4 and IL-8 have been speci®cally implicated in airway in¯ammation in the CF lung (1, 2) . Growth-related protein alpha (GROa) is a chemokine of the a sub-family and is structurally related to IL-8, but with even more potent neutrophil chemoattractant activity which is exerted via the IL-8 receptor (3). Previously described as growth-related oncogene product a and melanocyte growth-stimulating activity (MGSA), GROa is released in response to IL-1, TNFa and other pro-in¯ammatory stimuli acting on melanoma and other malignant cells, and also from normal cells including monocyte±macrophages, platelets and endothelial cells. GROa is implicated in conditions characterized by chronic neutrophilic in¯ammation, such as psoriasis and rheumatoid arthritis (4, 5) , and levels of GROa 3-to 7-fold higher than those of IL-8 have been found in bronchoalveolar lavage (BAL)¯uid from patients with bacterial pneumonia, adult respiratory distress syndrome and Pneumocystis pneumonia (6) . However, the role of GROa in CF has never been explored. We hypothesized that GROa may be important in perpetuating neutrophilic in¯ammation in the CF lung.
The severity of lung disease varies enormously in patients with CF, even between siblings and between non-related patients with the same CFTR genotype. It is likely that genetic and environmental factors interact to cause this heterogeneity, and many of these factors are unclear. While neutrophilic in¯ammation usually occurs in response to infection, high levels of in¯ammatory markers have also been demonstrated in bronchoalveolar lavage¯uid (BALF) of CF infants for whom clinical and microbiological evidence of associated infection is unconvincing (7, 8) . We have previously described the adverse in¯uence of positive atopic status on lung function in CF, and its association with increased production of bronchoconstrictor cysteinylleukotrienes, compared to non-atopic CF patients (9, 10, 11) . We hypothesized that atopic CF patients may also overproduce the neutrophil chemotaxin LTB 4 . Since LTB 4 has immunomodulatory actions in regulating cytokine expression by mononuclear cells (12,13) a putative overproduction of LTB 4 may lead to enhanced neutrophil migration in atopic CF patients compared to non-atopic CF patients not only by direct chemotaxis, but also indirectly by inducing expression of IL-8 and/or GROa from other cells.
We aimed therefore, ®rstly to determine whether GROa is present in the sputum and plasma of CF patients at biologically-signi®cant levels, and secondly, to relate atopic status to sputum levels of IL-8, GROa and LTB 4 , and to impairment of lung function.
Methods

PATIENT RECRUITMENT AND SAMPLE COLLECTION
Ethical approval was obtained from King's Healthcare and Great Ormond Street Hospital for Children, Research Ethics Committees. Samples of sputum (n25) and plasma (n24) were collected from CF patients recruited at these regional paediatric clinics. The diagnosis of CF had been con®rmed by sweat sodium levels above 60 mmol l 71 and/ or by the presence of two known CF gene mutations. The atopic CF patients were de®ned by one or more positive skin reactions (! 3 mm compared to control) to a panel of eight common allergens (cat and dog hair, house dust mite, house dust, mixed moulds, tree and grass pollens, mixed feathers). Mean (+SD) ages of the atopic CF patients (13Á7+3Á3 yr) and non-atopic CF patients (12Á2+3Á6 yr) were not signi®cantly dierent. Lung function was assessed from spirometric measurements of forced expiratory volume (FEV 1 ) and forced vital capacity (FVC), expressed as a percentage of those predicted for age, sex and height (14) . Lung function was used to detect dierences between atopic and non-atopic CF patients and was also correlated with sputum levels of LTB 4 , IL-8 and GROa. Subjects were excluded by the use of corticosteroids, theophylline or nonsteroidal anti-in¯ammatory drugs within the preceding four weeks. Control plasma was obtained from 25 healthy children (9Á33+3Á1 yr) having routine blood sampling prior to minor surgical procedures. Seven of the control subjects had positive skin prick tests, and four other controls, with negative skin tests, were considered to be atopic on the basis of an elevated serum total IgE (with levels of 806, 863 and two 41000 IU/ml respectively).
Where possible sputum was obtained from CF patients when they were clinically stable. However four subjects were only able to expectorate sputum whilst on IV antibiotics for an exacerbation. Their sputum IL-8 and LTB 4 levels were no greater than the other patients and they had undetectable GROa levels. The volume of sputum available for analysis from the remainder of the subjects was limited and tests for GROa and IL-8 were prioritized. Sputum samples were collected onto ice and stored at 7208C. Initial mucolysis was achieved using an equal volume of 100% N-acetylcysteine. Samples were then lique®ed by homogenization and debris removed by lowspeed centrifugation. The supernatant was divided into separate aliquots for analysis of LTB 4 and cytokines. Blood anti-coagulated with EDTA was collected onto ice, centrifuged within 30 min and the plasma stored at 7208C.
HPLC/RADIOIMMUNOASSAY OF LTB 4 IN SPUTUM
Lique®ed sputum samples from 14 of the 25 CF patients (eight atopic, six non-atopic) were available for LTB 4 analysis. Tritium-labelled LTB 4 (4nCi; Amersham, U.K.) was added to allow correction for losses of endogenous LTB 4 during puri®cation. The sputum was treated with four volumes of methanol at 48C for 30 min, and debris removed by centrifugation at 1000g for 20 min. The supernatant was evaporated to dryness and reconstituted in distilled water. LTB 4 was further puri®ed using Sep-Pak octadecylsilane cartridges (Millipore, Watforch, U.K.) and high performance liquid chromatography (HPLC) with reverse-phase C18 columns and a methanol/water mobile phase as described previously (1) . Radioimmunoassay (RIA) for LTB 4 was then performed as described (1) using a highly speci®c rabbit polyclonal antibody (gift of Dr A.W. Ford-Hutchinson, Merck-Frosst, Canada) with a minimum detection limit of approximately 20 pg ml 71 .
ENZYME IMMUNOASSAYS OF IL-8 AND GRO IN SPUTUM AND PLASMA
Interleukin-8 and GROa were measured in lique®ed sputum (n25) or plasma by speci®c and sensitive Quantikine enzyme linked immunosorbent assays (ELISA) (R&D Systems, Abingdon, U.K.) in accordance with the manufacturer's instructions. Samples were added to microtitre wells precoated with monoclonal antibody to the human recombinant cytokine and incubated for 2 h at room temperature. Wells were treated with a secondary antibody conjugated to horseradish peroxidase and bound cytokine visualized with tetramethylbenzidine chromogen and hydrogen peroxide by spectrophotometry at 450 nm. Assays were calibrated from a standard curve constructed using recombinant human cytokine over the range 0±6000 pg ml 71 for IL-8 and 0±1000 pg ml 71 for GROa. Minimum detection limits were consistent with those determined by the kit manufacturer (518Á1 pg ml 71 for IL-8 and 55 pg ml 71 for GROa).
STATISTICAL ANALYSIS
The normal range of GROa levels in sputum has not been fully established, which precluded power calculations, but the numbers of subjects in each group were based on previous published CF studies showing signi®cant dierences in cytokine and leukotriene levels (1,2,9). LTB 4 , IL-8 and GROa levels were non-normally distributed and group comparisons were performed by Mann±Whitney U-test for non-parametric data. Results are described as median and range. FEV 1 and FVC were normally distributed and group comparisons were performed by unpaired Student's t-test. These results are described as mean+SD. Analyses were performed using the Minitab statistical package and P 0Á05 was considered signi®cant.
Results
LUNG FUNCTION
FEV 1 was signi®cantly lower in atopic CF patients (41Á2+14.7% predicted, n12) than in non-atopic CF patients (59Á4+16Á6%; n13, P0Á008). FVC was also signi®cantly lower in the atopic CF group (54Á5+19Á7%) than in the non-atopic CF group (72+20Á9%, P0Á02).
The relatively poor lung function in both CF subgroups may re¯ect their selection as reliable producers of sputum samples.
SPUTUM IL-8, LTB 4 , AND GRO CONCENTRATIONS
Enzyme immunoassay showed that IL-8 was present at detectable levels (418Á1 pg ml
71
) in the sputum of nine out of 12 atopic CF patients and in 12 out of 13 non-atopic CF patients [ Fig. 1(a) ]. IL-8 concentrations were not signi®-cantly dierent in the atopic CF group (404 pg ml
, range 518Á1±7836) compared to the non-atopic CF group (738 pg ml 71 , range 518Á1±9008; P0Á18). Sputum also contained high levels of LTB 4 , with concentrations in atopic CF patients (723 pg ml
, range 301±1199, n8) not signi®cantly dierent from those in non-atopic CF patients (1020 pg ml
, range 571±3298, n6; P0Á3) [ Fig. 1(b) ]. In contrast, GROa levels were undetectable (55 pg ml 71 ) in 10 out of 12 atopic CF patients and in 11 out of 13 nonatopic CF patients [ Fig. 1(c)] . The remaining two patients in each CF subgroup had low GROa levels ranging from 144 to 824 pg ml 71 . Levels of IL-8, LTB 4 and GROa in CF sputum showed no signi®cant correlations with FEV 1 or FVC (r 2 0Á1, P !0Á1).
PLASMA IL-8 AND GRO CONCENTRATIONS
The CF group comprized 24 subjects as additional plasma samples were obtained from two atopic patients who were unable to produce sputum, and three of the non-atopic ) in 10 out of 12 atopic CF patients and in 11 out of 13 non-atopic CF patients. There were no signi®cant dierences between the atopic and non-atopic CF patients in sputum levels of IL-8, LTB 4 or GROa. subjects who had produced sputum were unwilling to provide a blood sample. The apparent division of control subjects into two groups according to their plasma IL-8 level [ Fig. 2(a) ] is considered arti®cial and the undetectable levels are likely to form a continuum. No normal subject had any evidence of an acute illness and the variation in values of IL-8 is reasoned to re¯ect the normal range in children. Enzyme immunoassay showed that median levels of IL-8 were signi®cantly higher in the plasma of CF patients (20 pg ml
71
, range 518Á1±58Á6, n24) than in the plasma of normal subjects (18Á3 pg ml
, range 518Á1± 24Á1, n25; P0Á02) [ Fig. 2(a) ]. IL-8 concentrations were not signi®cantly dierent between the atopic CF and nonatopic CF subgroups. Median levels of GROa in the plasma of CF patients (33 pg ml
, range 55±198, n24) were not signi®cantly dierent from those in normal subjects (34 pg ml 71 , range 55±64, n25; P40Á5), and there were also no signi®cant dierence in plasma GROa levels between the atopic CF and non-atopic CF subgroups [ Fig. 2(b) ]. Where paired samples were available from CF subjects IL-8 concentrations in plasma showed a correlation with those in sputum (r 2 0Á35, P0Á01). There was no correlation between plasma IL-8 (or GROa) levels and lung function.
Discussion
Characterization of the pro®le of factors that induce neutrophil in¯ux and activation in the CF lung may lead to novel speci®c anti-in¯ammatory therapies. Growthrelated protein a (GROa) is a highly potent member of the a sub-family of neutrophil chemokines, and is implicated in neutrophilic in¯ammation in other lung diseases (6) and in psoriasis and rheumatoid arthritis (4, 5) . This study is the ®rst to examine whether GROa may also contribute to the intense neutrophilia that leads to chronic lung damage in cystic ®brosis. The study con®rmed the ®ndings of previous studies (1,2) that two other neutrophil chemotaxins (IL-8 and LTB 4 ) are present in CF sputum at biologically-signi®cant concentrations. It also con®rmed elevated levels of IL-8 in the plasma of CF patients compared to normal subjects. However, speci®c enzyme immunoassays failed to detect GROa in 21 out of 25 CF sputum samples, and GROa was present only at low levels in the remaining four patients. Furthermore, GROa levels were not dierent in plasma from CF and normal subjects. The results suggest that GROa does not contribute to neutrophil in®ltration or activation in the CF lung.
FIG. 2.
Plasma levels of (a) IL-8 and (b) GROa in atopic (A) and non-atopic (NA) cystic ®brosis (CF) subjects and controls. Median values are shown as horizontal bars. In the CF group as a whole, IL-8 levels were signi®cantly higher than in controls (P0Á02), but GROa levels were not signi®cantly dierent from controls. There were no dierences between the atopic and non-atopic CF subgroups in plasma levels of IL-8 or GROa.
For a number of reasons, the lack of GROa in CF sputum is likely to re¯ect a true de®ciency due to impaired local production, and not a failure of detection: ®rstly, group sizes of 24±25 subjects provided a high level of statistical power to discriminate putative dierences in plasma GROa levels, and to detect GROa in sputum in a small proportion of CF patients. Secondly, the sensitivity of the enzyme immunoassay is sucient to detect GROa at concentrations one to three orders of magnitude lower than those at which it exerts its biological eects on neutrophils and other cells (3) . Thirdly, cytokine levels measured in CF sputum vary widely from study to study (15) , but we investigated GROa using techniques similar to those in a study in which signi®cant GROa levels were detected in BAL¯uid from patients with respiratory diseases other than CF (6) . Fourthly, the structurally-related a-family chemokine IL-8 was readily detected at nanomolar concentrations in the same sputum samples in which GROa levels were negligible; both IL-8 and GROa are likely to be degraded within the airway by non-speci®c proteases and there is no reason to suspect preferential degradation or dispersal of GROa. Indeed, other studies show good correlations between cytokine concentrations in BAL¯uid or sputum (2) . Fifthly, although sputum is a notoriously heterogeneous medium, liquefaction of sputum using the mucolytic dithiothreitol (DTT) does not appear to aect chemokine immunoreactivity (16, 17) . Sixthly, plasma levels of GROa are likely to represent overspill of macrophagederived GROa from the lung and elsewhere, and GROa was readily detected using the same methodology in the majority of plasma samples from both CF patients and normal controls.
Since GROa and IL-8 are produced in vitro by a similar range of cell-types (macrophages, endothelium) following stimulation by the same pro-in¯ammatory cytokines (IL-1, TNFa), it remains unclear why high IL-8 levels were seen in CF sputum in the absence of signi®cant GROa. Further work is required on the pro®le of stimuli in CF sputum and their eects on IL-8 and GROa gene transcription. However, if GROa had been present in CF sputum at similar molar levels to those of IL-8, the greater potency of GROa (3) would mean that GROa, not IL-8 would be the predominant ligand at the shared IL-8 receptor on neutrophils and other target cells. Our ®nding of negligible levels of GROa in CF sputum suggests that novel antiin¯ammatory agents need only block the binding of IL-8 to the shared receptor to reduce neutrophil migration in the CF lung.
The second aim of the study was to investigate whether sputum levels of neutrophil chemotaxins are dierent in atopic and non-atopic CF patients. Our previous studies showed that sputum cysteinyl-leukotriene (cys-LT) levels correlate with impairment of lung function in CF (10) , and that atopic CF patients have worse lung function and higher systemic cys-LT production (assessed by urinary LTB 4 levels) than non-atopic CF children (9, 11) . Since cysLTs and LTB 4 are formed from a common substrate by the 5-lipoxygenase pathway, which appears to be upregulated in atopy (18) , and since LTB 4 is found in CF sputum (1), we hypothesized that there may be excessive LTB 4 production in the atopic CF lung which could contribute to poorer lung function by inducing neutrophil migration, either by direct chemotaxis, or indirectly by enhancing expression of neutrophil chemokines such as IL-8 or GROa (12, 13) . Although the atopic CF subgroup did show signi®cantly lower FEV 1 and FVC values than their non-atopic counterparts, our hypothesis is contradicted by the lack of signi®cant dierences between the subgroups in sputum levels of LTB 4 , IL-8 and GROa, and in plasma levels of IL-8 and GROa, and by the lack of correlations with lung function. The measurements of lung function used in the study (FEV 1 and FVC) may better re¯ect the consequences of over-production of the potent bronchoconstrictor cysLTs. The atopic CF subgroup nevertheless remain an important subgroup who may gain additional bene®t from speci®c anti-in¯ammatory therapy in the future, particularly with cys-LT receptor antagonists. Clinical trials with a 5-lipoxygenase inhibitor would help to de®ne the contribution of LTB 4 to neutrophilic in¯ammation in CF.
In summary, the study found no evidence that the potent neutrophil chemokine GROa is over-produced in the CF lung, despite con®rming over-production of other neutrophil chemoattractants (IL-8, LTB 4 ) that are largely derived from similar cellular sources. Such a lack of GROa at the site of intense neutrophil in¯ammatory activity may even contribute to the inability of neutrophils in the CF lung to eradicate respiratory infections. This ®nding may nevertheless promote the development of novel therapies based upon antagonism of the restricted range of neutrophil chemotaxins with a probable pathophysiological role in the CF lung, especially LTB 4 and/or IL-8.
